Previous close | 0.2100 |
Open | 1.1000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 10.00 |
Expiry date | 2024-05-17 |
Day's range | 0.2100 - 1.1000 |
Contract range | N/A |
Volume | |
Open interest | 52 |
Q1 revenue of $19.7 million, increasing 51% year-over-yearQ1 gross profit increased 64% year-over-year to $12.2 million with a gross margin of 62%Won 9 DAAP deals during Q1 WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended March 31, 2024. Quarterly comparis
The consensus price target hints at a 34.8% upside potential for OptimizeRx (OPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: RBC Capital Markets Global Healthcare Conference, New York City, May 14 – 15, 2024B.Riley Securities 24th Annual Institutional Investor Conference, Beverly